Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT ID: NCT00770458
Last Updated: 2010-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2008-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
NCT00971334
Non-Invasive Screening for Fetal Aneuploidy
NCT00847990
Non-Invasive Screening for Fetal Aneuploidy
NCT02317965
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
NCT01052688
A New Prenatal Blood Test for Down Syndrome
NCT00877292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women
Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is pregnant
* Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure
* Subject is willing to provide blood specimen
Exclusion Criteria
* Subject is not willing to provide blood specimen
* Subject is not haveing aneuploid screening
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sequenom, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sequenom, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allan Bombard, MD
Role: STUDY_DIRECTOR
Sequenom, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Fetal Care & Genetics Center
La Jolla, California, United States
San Diego Perinatal Center
San Diego, California, United States
Obstetrix Medical Group of San Jose
San Jose, California, United States
Obstetrix Medical Group of Colorado
Denver, Colorado, United States
Women & Infants
Providence, Rhode Island, United States
A.R.U.P.
Salt Lake City, Utah, United States
Obstetrix Medical Group of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SQNM-Trisomy21-0100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.